Effect of Epstein-Barr Virus Sequence Variation on Performance of the Roche Real-Time LightCycler PCR Assay

Feng, Tao; Ye, Fei; Wu, Josephine W.; Jiang, Shiquan; Coolbaugh, Jennifer; Shneider, Benjamin L.; Herold, Betsy C.; Emre, Sükrü; Zhang, David Y.

doi:10.1128/jcm.02363-07

Cited by 4 publications

(5 citation statements)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EBER staining was, however, positive in all 11. Thus, the lack of detection of EBV by qcPCR may have been secondary to technical issues with the assay (16). The median interval between the first detection of EBV by qcPCR and development of PTLD in the nine patients with detectable EBV DNA was 3.3 months (range 2.3–94.2 months), and the median interval between immunosuppressive change and development of PTLD was one month (range 2 wk–2.6 yr).…”

Section: Resultsmentioning

confidence: 99%

“…The median interval between the first detection of EBV by qcPCR and development of PTLD in the nine patients with detectable EBV DNA was 3.3 months (range 2.3–94.2 months), and the median interval between immunosuppressive change and development of PTLD was one month (range 2 wk–2.6 yr). One recipient in Era A with monomorphic PTLD was diagnosed at the time of initial EBV DNA detection, and another with polymorphic PTLD had biopsy specimens consistent with EBV disease but undetectable EBV DNA by PCR (17). The specific changes in immunosuppression in response to the detection of EBV in the blood by PCR are detailed in Table 2.…”

Section: Resultsmentioning

confidence: 99%

“…One patient in our study had evidence of EBV by tissue biopsy but remained negative for detectable EBV PCR (Patient A5), and another did not develop a detectable EBV PCR until the time of disease diagnosis (Patient A4). The latter case reflected a sequence variation which resulted in negative PCR results (17).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

Kerkar

Morotti

Madan

et al. 2010

Pediatric Transplantation

Self Cite

View full text Add to dashboard Cite

Pediatric PTLD is often associated with primary EBV infection and immunosuppression. The aim was to retrospectively review the spectrum of histologically documented PTLD for two time intervals differentiated by changes in use of molecular EBV monitoring. Eleven of 146 patients (7.5%) in 2001-2005 (Era A) and 10 of 92 (10.9%) in 1993-1997 (Era B) were diagnosed with PTLD. The median age at liver transplantation (0.8 and 0.9 yr, respectively) and the median duration between liver transplant and diagnosis of PTLD (0.6 and 0.7 yr, respectively) were similar in both eras. However, patients in Era A presented with significantly less advanced histological disease compared to patients in Era B (p=0.03). Specifically, nine patients (82%) in Era A had Pl hyperplasia/polymorphic PTLD, whereas in Era B, six had advanced histological disease (five monomorphic and one unclassified). Three transplant recipients in Era B died secondary to PTLD, whereas there were no PTLD-related deaths in Era A (p=0.03). Heightened awareness of risk for PTLD, alterations in baseline immunosuppression regimens, implementation of molecular EBV monitoring, pre-emptive reduction in immunosuppression and improved therapeutic options may have all contributed to a milder PTLD phenotype and improved clinical outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

Kerkar

Morotti

Madan

et al. 2010

Pediatric Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…In immunosuppressed individuals, EBV is associated with post transplant lymphoproliferative diseases and AIDS-related lymphomas (1)(2)(3). Reliable detection and accurate monitoring of EBV DNA levels support clinical management, allowing early and tailored therapy (4)(5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

“…Today, molecular assays for detection and quantitation of EBV DNA have been implemented in the routine diagnostic laboratory and have replaced serological testing, especially for immunosuppressed patients (4)(5)(6)(7)(8)(9)(10). Molecular assays based on detection of EBV DNA from whole blood or plasma allow for rapid diagnosis of established EBV infections (4,6,11).…”

Section: Introductionmentioning

confidence: 99%

Detection and quantitation of Epstein-Barr virus (EBV) DNA in EDTA whole blood samples using automated sample preparation and real time PCR

Raggam

Wagner

Bozic

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

Viral infections in pediatric solid organ transplantation recipients and the impact of molecular diagnostic testing

Madan

Herold

2010

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

Effect of Epstein-Barr Virus Sequence Variation on Performance of the Roche Real-Time LightCycler PCR Assay

Cited by 4 publications

References 4 publications

The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

Detection and quantitation of Epstein-Barr virus (EBV) DNA in EDTA whole blood samples using automated sample preparation and real time PCR

Viral infections in pediatric solid organ transplantation recipients and the impact of molecular diagnostic testing

Contact Info

Product

Resources

About